UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

Fusion Antibodies plc (LON:FAB – Get Free Report) shares dropped 1.2% on Friday . The company traded as low as GBX 4.20 ($0.05) and last traded at GBX 4.25 ($0.05). Approximately 116,900 shares were ...

ArkBio has concluded enrolment and dosing for a Phase I trial of AK0610, to prevent RSV infection, particularly in vulnerable ...

Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego. “These ...

There are approx. 25+ key companies which are developing the therapies for Cutaneous T-cell lymphoma. The companies which have their Cutaneous T-cell lymphoma drug candidates in the most advanced ...

In this study, our results uncover the function and mechanism of CHMP5 in the regulation of cell senescence and bone formation in osteogenic cells. Deletion of Chmp5 causes endolysosomal dysfunction ...

A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

Fusion Antibodies PLC is engaged in the research, development and manufacturing of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...